Shifting Gears at GrowBLOX Sciences, Inc. (GBLX)
Medical cannabis and cannabinoid-based therapies are gaining wider acceptance around the United States. More than 20 states and the District of Columbia have legalized the drug and, between 2009 and 2014, IBISWorld estimates that the medical cannabis industry grew significantly to reach $2 billion in revenue. Despite this industry boom and the pioneers that emerged within it, there has been a shortage of companies conducting legitimate research and development and/or with the right amount of scientific backing and funding needed to compete in the industry.
GrowBLOX Sciences, a biopharmaceutical research and development company, stands out from the pack with its advanced technologies in plant biology and cultivation. Led by an impressive scientific team that includes big data experts, the company has turned its attention to creating safe, standardized pharmaceutical-grade cannabis-based therapies that target an assortment of medical conditions. The company is focused on bringing relief to patients in communities across the country by combining ground-breaking technology and industry processes with its “big” data-driven clinical research and development loop ability. Moreover, through its Puerto Rico subsidiary, GrowBLOX Sciences is developing and dispensing its suite of cultivation and growing chambers worldwide.
With its novel approach to using big data to produce lower-risk clinical trial candidates, GrowBLOX is highlighting its strong long-term potential. With over 180 cannabis-related human trials registered with the National Institute of Health (NIH) and more on the way, the company has established a brilliant starting point with close to a thousand potential combinations within the cannabinoid-related therapy space.
In the short term, the company intends to earn revenue from selling certified raw materials through dispensaries. These near-term plans were set in May when the company announced the formation of GrowBLOX Sciences Puerto Rico, a subsidiary that will legally grow cannabis raw materials that will be sold solely to its parent company for dispersion in the U.S. and other countries where the drug is legal.
The company’s operations – cultivation, post-processing and manufacturing – create a model platform to execute these visions. On the cultivation side, its TissueBLOX, GrowBLOX and CureBLOX platforms facilitate the efficient growing of cannabis, while its ExtractionLab produces proprietary blends for distribution as pharmaceuticals, nutraceuticals and cosmeceuticals. Given its distinctive business model, long-term potential in pharmaceuticals and short-term potential in raw material sales, GrowBLOX Sciences is a company worth a closer look.
For more information, visit the company’s website at www.growblox.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
Medical cannabis and cannabinoid-based therapies are gaining wider acceptance around the United States. More than 20 states and the District of Columbia have legalized the drug and, between 2009 and 2014, IBISWorld estimates that the medical cannabis industry grew significantly to reach $2 billion in revenue. Despite this industry boom and the pioneers that emerged within it, there has been a shortage of companies conducting legitimate research and development and/or with the right amount of scientific backing and funding needed to compete in the industry.
GrowBLOX Sciences, a biopharmaceutical research and development company, stands out from the pack with its advanced technologies in plant biology and cultivation. Led by an impressive scientific team that includes big data experts, the company has turned its attention to creating safe, standardized pharmaceutical-grade cannabis-based therapies that target an assortment of medical conditions. The company is focused on bringing relief to patients in communities across the country by combining ground-breaking technology and industry processes with its “big” data-driven clinical research and development loop ability. Moreover, through its Puerto Rico subsidiary, GrowBLOX Sciences is developing and dispensing its suite of cultivation and growing chambers worldwide.
With its novel approach to using big data to produce lower-risk clinical trial candidates, GrowBLOX is highlighting its strong long-term potential. With over 180 cannabis-related human trials registered with the National Institute of Health (NIH) and more on the way, the company has established a brilliant starting point with close to a thousand potential combinations within the cannabinoid-related therapy space.
In the short term, the company intends to earn revenue from selling certified raw materials through dispensaries. These near-term plans were set in May when the company announced the formation of GrowBLOX Sciences Puerto Rico, a subsidiary that will legally grow cannabis raw materials that will be sold solely to its parent company for dispersion in the U.S. and other countries where the drug is legal.
The company’s operations – cultivation, post-processing and manufacturing – create a model platform to execute these visions. On the cultivation side, its TissueBLOX, GrowBLOX and CureBLOX platforms facilitate the efficient growing of cannabis, while its ExtractionLab produces proprietary blends for distribution as pharmaceuticals, nutraceuticals and cosmeceuticals. Given its distinctive business model, long-term potential in pharmaceuticals and short-term potential in raw material sales, GrowBLOX Sciences is a company worth a closer look.
For more information, visit the company’s website at www.growblox.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
